Gene Expression is an open-access journal dedicated to publishing research at the intersection of science, biology, and medicine. The journal’s mission is to advance human health by providing a platform for disseminating the latest research breakthroughs from biomedical, translational, and basic scientists across both established and emerging disciplines relevant to human translational biomedicine. It was launched in 1991 by Chicago Medical School Press and transferred to Cognizant Communication Corporation in 1994. Since August 2022, Gene Expression has been published by Xia & He Publishing Inc.

Gene Expression publishes peer-reviewed, high-quality original articles, reviews, editorials, commentaries, and opinions on core research topics, including cell biology, molecular biology, genes, and genetics, with a particular focus on the cellular and molecular mechanisms underlying human diseases, specifically in areas such as cardiovascular disease, immunology and vaccines, metabolism, diabetes and obesity, neuroscience, cancer, infectious diseases, aging, biomarkers, gene and cellular therapy, animal models of human diseases, medical integrative omics analysis, epigenetics and regulatory RNAs, and other interdisciplinary approaches.

Examples of content in Gene Expression:

• Investigative studies of human biology, with an emphasis on disease.
  
• Research on models of human disease with significant implications for treatment.
  
• Focus articles, Perspectives, and Reviews that discuss medically relevant research from both basic science and clinical viewpoints.
  
• Special issues featuring comprehensive reviews and analyses of current topics in translational biomedicine.

Gene Expression is indexed in Medline (1991-2021), Scopus, Biological Abstracts, Biosis Previews, ProQuest, and other databases.

Mission

Gene Expression (GE) adopts open access publishing model, and all articles are distributed under the terms of the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/). Under this license, anyone may copy, distribute, or reuse these articles for non-commercial purposes, provided the original work is properly cited. Manuscripts submitted for publication in an open access journal are subject to the same rigorous peer-review and quality control as in scholarly subscription journals.

GE recognizes the distinct advantages of using an open access publication model to timely disseminate innovative and important research findings. Unrestricted free access to our publications is anticipated to foster intellectual discourse across geographic and disciplinary boundaries. To support the success of our open access approach, we ensure the integrity and high quality of research published in our journal by practicing a rigorous peer review process and by following strict guidelines for ethics in publication and in conduct of the scientific process.

All manuscripts submitted to GE must meet the following criteria for publication:

• Topics with timely relevance to the general field or specialties in basic and clinical medicine;
• Results and findings that have not been previously published elsewhere;
• Research performed with adherence to accepted global standards for ethics in the scientific process;
• Ethical reporting of data to protect the rights and privacy of study participants;
• Appropriate statistical analyses, with sufficient descriptions of all statistical methods used;
• Conclusions supported by the data presented;
• All funding sources and their roles cited;
• For clinical trials, the registration number cited;
• Manuscript written in standard American (US) English and formatted according to the journal-specific guidelines;
• No instances of textual plagiarism, including ‘text recycling/self-plagiarism”.

GE currently publishes 4 issues a year.

GE adopts the open access publishing model. Revenues are generated from article processing charges, permission fees, and reprints.

GE is owned and published by Xia & He Publishing Inc.